Harmony Biosciences Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Harmony Biosciences's estimated annual revenue is currently $21.5M per year.
- Harmony Biosciences received $200.0M in venture funding in March 2019.
- Harmony Biosciences's estimated revenue per employee is $144,597
- Harmony Biosciences's total funding is $495M.
- Harmony Biosciences has 149 Employees.
- Harmony Biosciences grew their employee count by 166% last year.
- Harmony Biosciences currently has 2 job openings.
|Cate McCanless||Vice President External Affairs|
|Julie Brown||Strategic Market Director-National & Regional Accounts|
|Michele Kemp||Director, Patient Engagement|
|Kate Holland||VP, Patient Engagement & Digital Marketing|
|David Knouft||Vice President, U.S. Market Access|
|Jill Charbonneau||Director Regulatory Affairs|
|Jeffrey Dayno||Executive Vice President and Chief Medical Officer|
|Michele Roy||Vice President, Regulatory Affairs|
|Joyce Ercolino||Director, Digital Excellence|
|Matt Fenske||Vice President Lifecycle & Portfolio Strategy|
What Is Harmony Biosciences?
Patients are at the beginning, middle, and heart of all we do. Harmony Biosciences, LLC, is a privately-owned biopharmaceutical company. The company was established in October 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. Harmony Biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Harmony Biosciences News
Harmony Biosciences, LLC (Harmony) has announced that the U.S. Food and Drug Administration (FDA) approved WAKIX® (pitolisant) for the ...
PLYMOUTH MEETING, Pa., Aug. 15, 2019 /PRNewswire/ -- Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and ...
The Plymouth Meeting company is seeking approval of its experimental therapy targeting narcolepsy and cataplexy.
Harmony Biosciences Funding
|2019-03-14||$200.0M||Undisclosed||CR Group LP||Article|
Harmony Biosciences New Location/Offices